Imunon IDMC backs continued Phase 2 IMNN-001 MRD study after safety review

Bitget2026/09/22 12:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Imunon’s independent monitoring committee backed continued Phase 2 testing of IMNN-001 in an ovarian cancer MRD study with no changes.
Safety review found no new signals, supporting the program’s differentiated tolerability profile across combination and maintenance use.
Preliminary Phase 2 MRD results were presented in July, pointing to deeper anti-tumor activity and immune activation versus control.
Clean safety read-through also supported ongoing execution of the pivotal Phase 3 OVATION 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220805PRIMZONEFULLFEED9831098) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Imunon IDMC backs continued Phase 2 IMNN-001 MRD study after safety review

You may also like

Crypto prices